Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved.
| Revenue (Most Recent Fiscal Year) | $154.01M |
| Net Income (Most Recent Fiscal Year) | $-309.85M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -431.71% |
| Net Margin (Trailing 12 Months) | -430.93% |
| Return on Equity (Trailing 12 Months) | -52.07% |
| Return on Assets (Trailing 12 Months) | -15.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.87 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 7.05 |
| Inventory Turnover (Trailing 12 Months) | 2.07 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 300.08M |
| Free Float | 292.58M |
| Market Capitalization | $312.09M |
| Average Volume (Last 20 Days) | 9.29M |
| Beta (Past 60 Months) | 2.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.50% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |